Search for: "Hospira"
Results 1 - 20
of 487
Sort by Relevance
|
Sort by Date
27 Mar 2024, 4:46 pm
Hospira, Inc., 944 F.3d 1327 (Fed. [read post]
27 Mar 2024, 10:56 am
Hospira, Inc., holding that challenged jury instructions “struck the appropriate balance by telling the jury that [defendant]’s additional underlying purposes [for alleged safe harbor activity] do not matter as long as [defendant] proved that the manufacture of any given batch of drug substance was reasonably related to developing information for FDA submission. [read post]
5 Mar 2024, 10:23 am
Hospira, Inc., 946 F.3d 1333 (Fed. [read post]
21 Dec 2023, 9:41 am
Hospira, Inc., 946 F.3d 1333, 1340 (Fed. [read post]
31 Jul 2023, 1:51 pm
Hospira, Inc., 946 F.3d 1333, 1338 (Fed. [read post]
31 Jul 2023, 1:47 pm
” Hospira, Inc. v. [read post]
11 Apr 2023, 2:44 pm
” Hospira, Inc. v. [read post]
14 Mar 2023, 4:09 pm
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
13 Feb 2023, 9:12 pm
By Kevin E. [read post]
22 Sep 2022, 9:43 am
Hospira, Inc., 827 F.3d 1363 (Fed. [read post]
14 Sep 2022, 12:42 am
Second, even if a product-by-process claim for a medical device is achieved, the enforceability of such a claim represents a challenge in and of itself (Hospira v Genentech ([2014] EWHC 3857, IPKat)). [read post]
14 Aug 2022, 8:16 pm
Hospira, Inc., 805 F.3d 1112, 1121 (Fed. [read post]
8 Aug 2022, 7:11 am
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
29 Jul 2022, 12:22 pm
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
23 Mar 2022, 8:23 am
Hospira, Inc., 52 F. [read post]
5 Mar 2022, 6:35 pm
Hospira, Inc., 946 F.3d 1333, 1337 (Fed. [read post]
7 Feb 2022, 10:32 am
Hospira, Inc., the Eleventh Circuit extended the POM Wonderful rule to Lanham Act claims concerning drug labels. 1 F.4th 1374, 1380–81 (11th Cir. 2021). [read post]
10 Nov 2021, 3:08 am
Hospira, Inc., No. 2020-1799 (Fed. [read post]
10 Nov 2021, 3:08 am
Hospira, Inc., No. 2020-1799 (Fed. [read post]
2 Nov 2021, 9:51 am
Hospira, reinforces the need for applicants to ensure they are fulfilling the duty of disclosure to the Patent Office consistent with their regulatory dossiers and communications. [read post]
